


RMC Acquired by Syner-G, a Portfolio Company of Riverside Partners, to Expand Regulatory Compliance Solutions



Increasing regulatory pressure combined with escalating demand for faster drug development is expected to drive the market for pharmaceutical regulatory compliance services to nearly \$15 billion by 2028. Within this growing market is Chemistry, Manufacturing and Control (CMC) and regulatory compliance services, which ensure that pharmaceutical companies and CDMOs comply with FDA regulations throughout the various stages of drug development.

RMC Pharmaceutical Solutions (RMC) is a leading provider of expert technical services focused on solving CMC issues in the biotechnology and pharmaceutical industry.

RMC provides a diverse range of technical and consulting services including process, analytical and formulation development, quality control and assurance, GLP/GMP manufacturing of API and drug product, and packaging/distribution. The company's service offerings were the ideal strategic complement to enhance Syner-G's existing suite of comprehensive CMC solutions.

Crosstree's granular knowledge of the drug development marketplace helped RMC evaluate both financial and strategic partners using real world data, not just hypotheses, and select the ideal partner to accelerate its future growth.

Crosstree helps its clients identify optimal transaction partners to enhance value for all stakeholders.

ABOUT RMC



Founded in 2004, RMC is the leading global provider of Bolt-on CMC® expert services to the pharmaceutical, biotechnology, medical device and allied industries. RMC provides experienced integrated teams to directly support Chemistry, Manufacturing and Control (CMC) services in areas such as process, analytical and formulation development; quality control/quality assurance; and oversight of GMP manufacturing for more than 350 different clients across North America, Europe, Australia, South America and Asia. RMC experts support the full range of GxP pharmaceutical development and commercialization activities.

ABOUT SYNER-G BIOPHARMA GROUP



Headquartered in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, and regulatory submission and publishing solutions and services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON
Director

jason.layton@crosstreecapital.com
813-578-7109